Source link : https://newshealth.biz/health-news/oral-glp-1-receptor-antagonist-reduces-cv-risk/
CHICAGO — In patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, chronic kidney disease, or both, the oral formulation of semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, reduces the risk for major adverse cardiovascular events, according to SOUL, an international phase 3b placebo-controlled trial. The result is “consistent with prior studies of […]
The post Oral GLP-1 Receptor Antagonist Reduces CV Risk first appeared on News Health.
Author : News Health
Publish date : 2025-03-30 17:30:00
Copyright for syndicated content belongs to the linked Source.
in Health